DAMATO, Valentina
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.776
AS - Asia 2.479
EU - Europa 2.117
SA - Sud America 524
Continente sconosciuto - Info sul continente non disponibili 98
AF - Africa 75
OC - Oceania 19
Totale 9.088
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.666
RU - Federazione Russa 863
SG - Singapore 704
IT - Italia 702
CN - Cina 602
BR - Brasile 428
HK - Hong Kong 282
VN - Vietnam 272
KR - Corea 207
IE - Irlanda 170
BD - Bangladesh 120
FR - Francia 81
IN - India 68
CA - Canada 67
SE - Svezia 65
ID - Indonesia 60
FI - Finlandia 56
DE - Germania 52
GB - Regno Unito 47
AR - Argentina 43
JP - Giappone 31
NL - Olanda 26
TH - Thailandia 23
IQ - Iraq 21
CI - Costa d'Avorio 20
AU - Australia 19
EC - Ecuador 19
MX - Messico 19
UA - Ucraina 18
MA - Marocco 15
PH - Filippine 15
MY - Malesia 14
ZA - Sudafrica 14
CO - Colombia 11
UZ - Uzbekistan 9
AE - Emirati Arabi Uniti 8
NG - Nigeria 8
EG - Egitto 6
PE - Perù 6
PK - Pakistan 6
AT - Austria 5
ES - Italia 5
HN - Honduras 5
TR - Turchia 5
BE - Belgio 4
BJ - Benin 4
CL - Cile 4
IR - Iran 4
KE - Kenya 4
KZ - Kazakistan 4
PY - Paraguay 4
SA - Arabia Saudita 4
SV - El Salvador 4
TT - Trinidad e Tobago 4
UY - Uruguay 4
AZ - Azerbaigian 3
LB - Libano 3
LT - Lituania 3
OM - Oman 3
PL - Polonia 3
PS - Palestinian Territory 3
VE - Venezuela 3
AL - Albania 2
BB - Barbados 2
BH - Bahrain 2
BO - Bolivia 2
BY - Bielorussia 2
CH - Svizzera 2
CR - Costa Rica 2
DO - Repubblica Dominicana 2
ET - Etiopia 2
HU - Ungheria 2
JM - Giamaica 2
PR - Porto Rico 2
PT - Portogallo 2
SY - Repubblica araba siriana 2
AF - Afghanistan, Repubblica islamica di 1
BA - Bosnia-Erzegovina 1
CZ - Repubblica Ceca 1
GR - Grecia 1
IS - Islanda 1
JO - Giordania 1
KH - Cambogia 1
NI - Nicaragua 1
NO - Norvegia 1
QA - Qatar 1
RE - Reunion 1
RO - Romania 1
SK - Slovacchia (Repubblica Slovacca) 1
TN - Tunisia 1
Totale 8.990
Salva come PNG Salva come JPEG
Città #
Santa Clara 1.544
Singapore 539
Ashburn 418
Hong Kong 238
Seoul 204
Dublin 168
Hefei 167
Council Bluffs 128
Milan 126
Los Angeles 114
Ho Chi Minh City 112
San Jose 103
Kent 82
Altamura 80
Lawrence 80
Beijing 73
Rome 64
Hanoi 63
Buffalo 62
Moscow 59
Lauterbourg 55
Fairfield 47
Boston 46
Chicago 45
Jakarta 42
Princeton 41
Florence 40
São Paulo 38
New York 37
The Dalles 37
Bar Harbor 35
Mumbai 33
Tokyo 27
Helsinki 25
Munich 24
Wilmington 24
Bangkok 23
Naples 23
Shanghai 23
Lappeenranta 21
Abidjan 20
Salt Lake City 20
Turin 19
Dallas 18
Melbourne 18
San Diego 18
Toronto 18
Figino 16
Frankfurt am Main 16
London 16
Seattle 15
Baghdad 12
Genoa 12
Verona 12
West Jordan 12
Montreal 11
Casablanca 10
Da Nang 10
Dulles 10
Hillsboro 10
Quito 10
Rio de Janeiro 10
Tianjin 10
Turku 10
Woodbridge 10
Atlanta 9
Elk Grove Village 9
Goiânia 9
Orem 9
Tampa 9
Tashkent 9
Belo Horizonte 8
Bengaluru 8
Bologna 8
Curitiba 8
Guangzhou 8
Haiphong 8
Medford 8
Miano 8
Padua 8
Pune 8
Yubileyny 8
Abuja 7
Bari 7
Brasília 7
Cambridge 7
Guarulhos 7
Kuala Lumpur 7
Kuala Selangor 7
Manila 7
Andover 6
Brooklyn 6
Denver 6
Houston 6
Johannesburg 6
Lima 6
Mexico City 6
Miami 6
Palermo 6
Pescara 6
Totale 5.711
Salva come PNG Salva come JPEG
Nome #
Teaching Video NeuroImage: The “Chameleon Eyes Sign” in Myasthenia Gravis 286
Serological Markers of Clinical Improvement in MuSK Myasthenia Gravis 252
Comparison of Fixed and Live Cell-Based Assay for the Detection of AChR and MuSK Antibodies in Myasthenia Gravis 234
Safety and effectiveness of the booster dose of mRNA COVID-19 vaccines in people with multiple sclerosis: A monocentric experience 194
Cervical lymph nodes and ovarian teratomas as germinal centres in NMDA receptor-antibody encephalitis 193
Safety and tolerability of SARS-Cov-2 vaccination in patients with myasthenia gravis: A multicenter experience 189
Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study 189
Efficacy and safety of rituximab in myelin oligodendrocyte glycoprotein antibody-associated disorders compared with neuromyelitis optica spectrum disorder: a systematic review and meta-analysis 177
Leptomeningeal enhancement in multiple sclerosis: a focus on patients treated with hematopoietic stem cell transplantation 173
Long-term-video monitoring EEG and 18F-FDG-PET are useful tools to detect residual disease activity in anti-LGI1-Abs encephalitis: A case report 166
Rituximab abrogates aquaporin-4-specific germinal center activity in patients with neuromyelitis optica spectrum disorders 162
Clinical Course of Neurologic Adverse Events Associated With Immune Checkpoint Inhibitors 160
Conventional and emerging treatments and controversies in myasthenia gravis 153
Clinical value of cell-based assays in the characterisation of seronegative myasthenia gravis 151
Safety profile of SARS-CoV-2 vaccination in patients with antibody-mediated CNS disorders 150
Clinical, neurophysiological and serological clues for the diagnosis of neuromyotonia and distinction from cramp-fasciculation syndrome 149
Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis 149
The detection of neural autoantibodies in patients with antiepileptic-drug-resistant epilepsy predicts response to immunotherapy 148
Association Between a Distinctive Autoantibody-Associated Brainstem Sensory Syndrome and Immune Checkpoint Inhibitors 142
Clinical characteristics and outcome of patients with autoimmune encephalitis: clues for paraneoplastic aetiology 140
Clinical and immunological characteristics of the spectrum of GFAP autoimmunity: A case series of 22 patients 139
Hematopoietic Stem Cell Transplantation for the Treatment of Autoimmune Neurological Diseases: An Update 138
Consistent improvement with eculizumab across muscle groups in myasthenia gravis 134
Challenges in Diagnosis of COVID-19 Pneumonia under Ocrelizumab and De-Risking Strategies in Multiple Sclerosis—The Elephant Is (Still) in the Room 132
Long-term safety and efficacy of eculizumab in generalized myasthenia gravis 131
Serological and experimental studies in different forms of myasthenia gravis 130
Pattern of ocular involvement in myasthenia gravis with MuSK antibodies 129
Benefit and danger from immunotherapy in myasthenia gravis 128
The clinical features, underlying immunology, and treatment of autoantibody-mediated movement disorders 125
Immune Checkpoint Inhibitor-Related Cerebellar Toxicity: Clinical Features and Comparison with Paraneoplastic Cerebellar Ataxia 124
Clinical features and outcome of patients with autoimmune cerebellar ataxia evaluated with the Scale for the Assessment and Rating of Ataxia 124
Acetylcholine receptor antibody positivity rate in ocular myasthenia gravis: a matter of age? 121
Myasthenia gravis and related disorders 121
Tissue-infiltrating lymphocytes analysis reveals large modifications of the duodenal "immunological niche" in coeliac disease after gluten-free diet 120
Eculizumab improves fatigue in refractory generalized myasthenia gravis 120
Myasthenia gravis with antibodies to MuSK: An update 117
Human Leukocyte Antigen Class II associations in late-onset Myasthenia Gravis 115
Diagnostic algorithms in autoimmune encephalitis 113
‘Minimal symptom expression’ in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab 113
Circulating CD56dim NK cells expressing perforin are increased in progressive multiple sclerosis 112
Disease specific enrichment of circulating let-7 family microRNA in MuSK+ myasthenia gravis 112
Cerebellar degeneration associated with mGluR1 autoantibodies as a paraneoplastic manifestation of prostate adenocarcinoma 112
Anorexia heralding the onset of neuromyelitis optica 111
Eculizumab in refractory generalized myasthenia gravis previously treated with rituximab: subgroup analysis of REGAIN and its extension study 110
Creutzfeldt-Jakob disease manifesting as stroke mimic in a 78-year-old patient: Pitfalls and tips in the diagnosis 110
3,4-Diaminopyridine may improve myasthenia gravis with M u SK antibodies 109
Heterogeneity in myasthenia gravis: considerations for disease management 108
Myasthenia gravis associated with anti-MuSK antibodies developed after SARS-CoV-2 infection 107
Myasthenia gravis with presynaptic neurophysiological signs: Two case reports and literature review 106
In reply 104
Thymic hyperplasia after autologous hematopoietic stem cell transplantation in multiple sclerosis: a case series 103
Lower motor neuron involvement in longitudinally extensive transverse myelitis with and without aquaporin-4 antibodies 103
Remission of myasthenia gravis with MuSK antibodies during ruxolitinib treatment 102
Distinct lymphocytes subsets in IgM-related neuropathy: clinical-immunological correlations 101
When myasthenia gravis is not all 99
Immunological response after SARS-CoV-2 infection and mRNA vaccines in patients with myasthenia gravis treated with Rituximab 99
Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders: A systematic review and meta-analysis 98
Type 1 immune response in progressive multiple sclerosis 96
Neuromyelitis optica spectrum disorder as a paraneoplastic manifestation of lung adenocarcinoma expressing aquaporin-4 95
CD20+ T Cells in Multiple Sclerosis: From Pathogenesis to Treatment-Induced Depletion 93
Neuropathic pain in CASPR2 antibody disease spectrum: A systematic review 91
Poly-autoimmunity in patients with myasthenia gravis: A single-center experience 90
Response to: “MuSK-positive myasthenia may be triggered not only by SARS-CoV-2” 88
Epidemiology of seropositive myasthenia gravis in Sardinia: A population‐based study in the district of Sassari 86
Distinctive clinical and neuroimaging characteristics of longitudinally extensive transverse myelitis associated with aquaporin-4 autoantibodies 85
Risk of False Acetylcholine Receptor Autoantibody Positivity by Radioimmunoprecipitation Assay in Clinical Practice 59
Screening for Congenital Myasthenic Syndromes in Adults With Seronegative Myasthenia Gravis Using Next-Generation Sequencing 53
Validation of the MOG-AR Score 53
Validation of the "Patient-Acceptable Symptom State" Question as Outcome Measure in AChR Myasthenia Gravis: A Multicentre, Prospective Study 46
Typical and atypical clinical presentations 45
Early real-life experience on Zilucoplan for generalized myasthenia gravis: ZILU25 multicenter observational study 41
Efficiency of cell-based assays in detecting AChR antibodies in myasthenia gravis sera with low antibody concentrations as determined by radioimmunoprecipitation assay 29
Brain [18F]FDG-PET as a marker of disease activity in a case of CASPR2 limbic encephalitis 27
Cellular immune endophenotypes separating early and late-onset myasthenia gravis 27
Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): Practical recommendations for diagnosis and management 27
Real-Life Evaluation of the MOGAD Diagnostic Criteria 25
The gut microbiome associated with LGI1 ‐antibody encephalitis 23
Prediction, prevention, and precision treatment of immune checkpoint inhibitor neurological toxicity using autoantibodies, cytokines, and microbiota 22
Uveitis: A snapshot in the MOG antibody spectrum 19
Neurological adverse events of immune checkpoint inhibitors: A practical guide to diagnosis with a focus on neuroimaging findings 16
Therapeutic IgG- and IgM-specific proteases disarm the acetylcholine receptor autoantibodies that drive myasthenia gravis pathology 15
Totale 9.088
Salva come PNG Salva come JPEG
Categoria #
all - tutte 27.950
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 27.950
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022218 0 0 0 0 0 0 0 104 24 1 14 75
2022/2023491 68 161 16 17 0 89 89 3 19 10 13 6
2023/2024402 11 17 68 17 33 40 15 63 9 35 72 22
2024/20253.495 94 316 158 395 1.040 735 107 92 120 57 236 145
2025/20264.110 347 436 557 591 310 87 287 210 279 265 210 531
2026/2027372 241 131 0 0 0 0 0 0 0 0 0 0
Totale 9.088